

# THE LANCET

## Infectious Diseases




### Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Romero C, DíezJM, GajardoR. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products. *Lancet Infect Dis* 2021; published online Feb 16. [http://dx.doi.org/10.1016/S1473-3099\(21\)00059-1](http://dx.doi.org/10.1016/S1473-3099(21)00059-1).

## **Appendix for: Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products**

Figure 1. Anti-SARS-CoV-2 antibody titers in plasma pools of collected in Spain (A) and the U.S, (B) and in IVIG batches manufactured from the plasma collected in these countries (C). The red line shows the cut-off value (positive/negative). Since a humoral preexisting cross-reactivity with common seasonal coronavirus has been shown <sup>2,5</sup> a threshold value to determine the incorporation of specific Anti-SARS-CoV-2 antibodies was needed. This threshold is calculated using the mean of IVIG pre-Covid batches plus three standard deviations. Results above the threshold are considered positive for specific anti-SARS-CoV-2 antibodies and values below the threshold are considered to be due to cross-reactivity with seasonal coronavirus antibodies.






Figure 2. Anti-SARS-CoV-2 antibody titers in manufacturing plasma pools of plasma collected in Germany, Czechia, and Slovakia. Red line shows the cut-off value (positive/negative)

### Acknowledgments

The authors acknowledge the expert technical assistance of the personnel of the Quality Control Departments of Grifols Biologicals (Los Angeles, CA, USA), Grifols Therapeutics (Clayton, NC, USA) and Instituto Grifols SA (Barcelona, Spain), and the Immunotherapies Unit, Bioscience R&D, Scientific Innovation Office (Barcelona, Spain). Editorial assistance of the Grifols Scientific Publications Department is also acknowledged.